Peter Smibert
Papers
2
Total Citations
145
H-Index
2
About
Peter Smibert is a pioneering translational researcher whose work bridges functional genomics and personalized oncology. His key research areas include rare cancer therapeutics, Drosophila-based drug screening platforms, and precision medicine for treatment-refractory malignancies. Smibert’s major contributions center on developing innovative, organism-level screening systems to identify effective drug combinations for individual patients. His landmark 2019 study (107 citations) introduced a personalized platform using a robotics-based Drosophila hindgut screen, which identified trametinib plus zoledronate as a candidate therapy for a KRAS-mutant metastatic colorectal cancer patient. This treatment produced a strong partial response with 11 months of stable disease—a remarkable outcome for a notoriously difficult-to-treat mutation. In 2021 (38 citations), Smibert extended this approach to adenoid cystic carcinoma, a rare salivary gland cancer with limited treatment options, demonstrating the platform’s versatility. His work represents a paradigm shift from population-based trials to individualized functional testing, offering hope for patients with genomically complex or ultra-rare cancers. Smibert’s achievements highlight the power of cross-species modeling in delivering clinically actionable insights where conventional approaches fail.
Research Focus
Key Achievements
Top Papers
- 1
- 2